Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression

[1]  Zhaohui Zhu,et al.  A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer , 2022, The Journal of Nuclear Medicine.

[2]  M. Eder,et al.  [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer , 2022, Pharmaceuticals.

[3]  K. Pienta,et al.  Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer  , 2022, Expert review of anticancer therapy.

[4]  A. Rosenwald,et al.  Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  P. Khong,et al.  Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics , 2022, Theranostics.

[6]  Steffie M. B. Peters,et al.  [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Bartholomä,et al.  castration‐resistant prostate cancer: Initial 254‐patient results from a prospective registry (REALITY Study) Fadi Khreish1 · Zaidoon Ghazal1 · Robert J. Marlowe3 · Florian Rosar1 · Amir Sabet1 · Stephan Maus1 · Johannes Linxweiler2 · Mark Bartholomä1 · Samer Ezziddin1 , 2021 .

[8]  M. Eder,et al.  [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer , 2021, Pharmaceuticals.

[9]  Haibo Zhu,et al.  A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  M. Hatt,et al.  Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, 18F-FMISO PET, and 18F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma , 2021, The Journal of Nuclear Medicine.

[11]  S. Tagawa,et al.  Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer , 2021, Current Oncology Reports.

[12]  R. Schibli,et al.  Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  K. Rahbar,et al.  Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy , 2020, Theranostics.

[14]  F. Borgna,et al.  Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile , 2020, Molecules.

[15]  Xiaoyuan Chen,et al.  177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer , 2020, The Journal of Nuclear Medicine.

[16]  F. Borgna,et al.  Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity , 2020, Theranostics.

[17]  W. Horninger,et al.  The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  A. Buck,et al.  68Ga-PSMA I&T PET/CT for primary staging of prostate cancer , 2019, Nuklearmedizin.

[19]  Yi Cao,et al.  Maleimide–thiol adducts stabilized through stretching , 2019, Nature Chemistry.

[20]  D. Murphy,et al.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes , 2018, The Journal of Nuclear Medicine.

[21]  F. Bénard,et al.  Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies. , 2018, Molecular pharmaceutics.

[22]  Xiaoyuan Chen,et al.  Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. , 2018, Bioconjugate chemistry.

[23]  F. Bénard,et al.  Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model , 2018, The Journal of Nuclear Medicine.

[24]  R. Schibli,et al.  Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. , 2018, Molecular pharmaceutics.

[25]  Alexander Haug,et al.  Current status of theranostics in prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  G. Feldmann,et al.  The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  T. Holland-Letz,et al.  Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.

[29]  T. Poeppel,et al.  PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status , 2015, Theranostics.

[30]  U. Haberkorn,et al.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[31]  P. Senter,et al.  Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates , 2014, Nature Biotechnology.

[32]  J. Céraline,et al.  A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells , 2013, Cell biology international.

[33]  Slave Trajanoski,et al.  Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.

[34]  Angel Ortega,et al.  Glutathione in Cancer Biology and Therapy , 2006, Critical reviews in clinical laboratory sciences.

[35]  G Siest,et al.  Blood and plasma glutathione measured in healthy subjects by HPLC: relation to sex, aging, biological variables, and life habits. , 1995, Clinical chemistry.